Your browser doesn't support javascript.
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.
Pham, F Y-V; Jacquet, E; Monard, A; Brunel, L; Blay, J-Y; Albin, N.
  • Pham FY; Oncology Hematology and Cell Therapy Department, French National Agency for Safety of Medicines and Health Products, Saint-Denis, France; Department of Pharmacy, Centre hospitalo-universitaire Hôpital Henri Mondor Assistance Publique des Hôpitaux de Paris, Créteil, France.
  • Jacquet E; Department of Oncohematology, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
  • Monard A; Oncology Hematology and Cell Therapy Department, French National Agency for Safety of Medicines and Health Products, Saint-Denis, France; Department of Oncohematology, Avec Groupe Hospitalier Mutualiste, Grenoble, France.
  • Brunel L; Oncology Hematology and Cell Therapy Department, French National Agency for Safety of Medicines and Health Products, Saint-Denis, France.
  • Blay JY; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Albin N; Oncology Hematology and Cell Therapy Department, French National Agency for Safety of Medicines and Health Products, Saint-Denis, France; Department of Oncohematology, Avec Groupe Hospitalier Mutualiste, Grenoble, France. Electronic address: nicolas.albin@ansm.sante.fr.
Ann Oncol ; 33(5): 561-563, 2022 05.
Article in English | MEDLINE | ID: covidwho-1914142
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Technology Assessment, Biomedical / Neoplasms Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Ann Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: J.annonc.2022.02.002

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Technology Assessment, Biomedical / Neoplasms Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Ann Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: J.annonc.2022.02.002